336 related articles for article (PubMed ID: 24144876)
1. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
2. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
[TBL] [Abstract][Full Text] [Related]
3. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
Grau-López L; Teniente-Serra A; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Martínez-Cáceres EM; Ramo-Tello C
Mult Scler; 2015 Apr; 21(5):646-50. PubMed ID: 25145693
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
Ramo-Tello C; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Grau-López L
Mult Scler; 2016 Jan; 22(1):117-21. PubMed ID: 26540732
[TBL] [Abstract][Full Text] [Related]
6. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
Liu S; Liu X; Chen S; Xiao Y; Zhuang W
PLoS One; 2017; 12(11):e0188644. PubMed ID: 29176905
[TBL] [Abstract][Full Text] [Related]
7. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
[TBL] [Abstract][Full Text] [Related]
8. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
Hervás-García JV; Ramió-Torrentà L; Brieva-Ruiz L; Batllé-Nadal J; Moral E; Blanco Y; Cano-Orgaz A; Presas-Rodríguez S; Torres F; Capellades J; Ramo-Tello C
Eur J Neurol; 2019 Mar; 26(3):525-532. PubMed ID: 30351511
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
[TBL] [Abstract][Full Text] [Related]
11. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
12. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
[TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
[TBL] [Abstract][Full Text] [Related]
15. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
[TBL] [Abstract][Full Text] [Related]
16. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Burton JM; O'Connor PW; Hohol M; Beyene J
Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.
Oliveri RL; Valentino P; Russo C; Sibilia G; Aguglia U; Bono F; Fera F; Gambardella A; Zappia M; Pardatscher K; Quattrone A
Neurology; 1998 Jun; 50(6):1833-6. PubMed ID: 9633736
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
19. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
20. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
Smith D
J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
